title: [Management of jaundice in the newborn≥35 GW: From screening to follow-up after discharge. Guidelines for clinical practice].
abstract: Jaundice due to unconjugated bilirubin is an everyday condition in the neonatal period because it results from the adaptation of bilirubin metabolism at this time of life. Hyperbilirubinemia has a potential neurotoxicity and although it most often resolves spontaneously, it can lead to acute and sometimes chronic encephalopathy. The latter condition is called kernicterus and induces severe and irreversible neurological sequelae. This rare complication is still reported in all countries throughout the world even if severe hyperbilirubinemia can be prevented and critical points points of failure in jaundice management are identified. Jaundice management are identified, jaundice is the most frequent symptom during the first days of life and after discharge from the maternity ward but also the major cause of readmission in the 15 first days of life. Therefore in the past 20 years, numerous countries have written national practical guidelines for the management of neonatal jaundice using various methodologies. Most of the time, the guidelines resulted from expert consensus more than from an evidence-based argument. The Société française de néonatologie created a working group to provide the first French clinical guidelines for the management of jaundice in the near-term newborn (35 weeks and more). They were written following a physiopathological argument and taking into account both clinical risk factors for severe hyperbilirubinemia and interindividual variability in vulnerability to bilirubin neurotoxicity. Practical tools were also developed to facilitate implementation of the guidelines and are also included.
authors.affiliation: Unité fonctionnelle clinique du centre national de référence en hémobiologie périnatale (CNRHP), service de médecine fœtale, pôle périnatalité du GHU Est-Parisien, hôpital Trousseau, AP-HP, 26, avenue Arnold-Netter, 75012 Paris, France. Electronic address: anne.cortey@aphp.fr.
authors.forename: A
authors.initials: A
authors.lastname: Cortey
authors.affiliation: Néonatologie maternité, centre Aliénor-d'Aquitaine, CHU de Bordeaux, place Amélie- Raba- Léon, 33076 Bordeaux cedex, France.
authors.forename: L
authors.initials: L
authors.lastname: Renesme
authors.affiliation: Unité de néonatologie, hôpital des enfants, CHU de Toulouse, 330, avenue de Grande-Bretagne, TSA700 34, 31059 Toulouse cedex 9, France.
authors.forename: J
authors.initials: J
authors.lastname: Raignoux
authors.affiliation: Néonatologie, hôpital Mère-Enfant, CHU de Limoges, 2, avenue Martin-Luther-king, 87042 Limoges cedex, France.
authors.forename: A
authors.initials: A
authors.lastname: Bedu
authors.affiliation: Unité de néonatologie, hôpital des enfants, CHU de Toulouse, 330, avenue de Grande-Bretagne, TSA700 34, 31059 Toulouse cedex 9, France.
authors.forename: C
authors.initials: C
authors.lastname: Casper
authors.affiliation: Médecine néonatale et réanimation pédiatrique, pôle femme-couple-enfant, CHU Amiens Picardie, D408, 80054 Amiens cedex 1, France.
authors.forename: P
authors.initials: P
authors.lastname: Tourneux
authors.affiliation: Médecine néonatale, hôpital Jeanne-de-Flandre, CHRU de Lille, avenue Eugène-Avinée, 59000 Lille, France.
authors.forename: P
authors.initials: P
authors.lastname: Truffert
mesh_terms: D019317:Evidence-Based Medicine; D005500:Follow-Up Studies; D005602:France; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D007567:Jaundice, Neonatal / Q000175:diagnosis* / Q000628:therapy*; D008403:Mass Screening; D009359:Neonatology; D010351:Patient Discharge; D010359:Patient Readmission; D012955:Societies, Medical